8 Health claim verifications about United States Food and Drug Administration United States Food and Drug Administration ×
“The FDA approved soy protein isolate at a daily intake of 25g despite its own safety committee recommending a maximum of 150mg per day.”
The central allegation — that an FDA safety committee recommended a 150mg/day maximum for soy protein isolate — is not supported by any FDA document, Federal Register entry, or peer-reviewed source in the evidentiary record. While the FDA did authorize a heart-health label claim tied to 25g/day of soy protein, and two individual FDA scientists raised concerns about isoflavone-related effects, no formal committee ever set a 150mg/day protein limit. The claim conflates milligram-range isoflavone discussions with gram-range protein intake and mischaracterizes individual dissent as an official committee recommendation.
“Common cosmetic ingredients, when used at regulatory-approved doses, are toxic to human health.”
The evidence does not support the assertion that common cosmetic ingredients are toxic at regulatory-approved doses. Regulatory frameworks in the EU, Canada, and (post-MoCRA) the U.S. set approved doses well below observed adverse-effect thresholds, typically with 100x safety margins. Sources cited in support describe associations at unspecified exposure levels, regulatory gaps, or scientific uncertainty about long-term cumulative effects — none demonstrate toxicity at approved doses under normal use. The claim conflates hazard identification with actual risk at regulated exposure levels.
“BPC-157 and TB-500 peptide supplements are FDA-approved and have been scientifically proven to heal injuries and slow aging in humans.”
This claim is false on both of its core assertions. Neither BPC-157 nor TB-500 holds FDA approval for any therapeutic indication — the 2026 Category 1 reclassification permits compounding under physician oversight but is explicitly not FDA approval. The "scientifically proven" claim is equally unsupported: human evidence consists only of small, uncontrolled pilot studies, with no large-scale randomized controlled trials, and there is no human clinical evidence for anti-aging effects.
“Anktiva (nogapendekin alfa inbakicept) is approved and clinically effective for treating, curing, or preventing all types of cancer, not solely bladder cancer.”
Anktiva (nogapendekin alfa inbakicept) is approved only for BCG-unresponsive non-muscle-invasive bladder cancer with carcinoma in situ, as confirmed by the FDA, EMA, and all major clinical references. It is not approved for any other cancer type. While early-phase trials have explored its use in other malignancies, no regulatory body has recognized it as effective for treating, curing, or preventing "all types of cancer." The claim dramatically overstates both the drug's approved scope and its demonstrated efficacy.
“Dietary supplements containing undisclosed pharmaceutical drugs — including steroids, thyroid hormones, and amphetamine-like stimulants — have been sold to consumers for years with limited regulatory consequence due to insufficient FDA enforcement capacity.”
The claim is substantially accurate. Peer-reviewed research documents over 1,000 dietary supplements adulterated with undisclosed pharmaceuticals — including synthetic steroids and stimulants — sold from 2007 through 2021, with some products remaining on shelves years after FDA warnings. However, the specific inclusion of "thyroid hormones" as a central adulterant pattern is not well-supported by the evidence. Additionally, the enforcement gap stems primarily from DSHEA's statutory design (classifying supplements as foods), not purely from insufficient FDA capacity — a meaningful distinction the claim obscures.
“Collagen supplements in the United States are largely unregulated by the Food and Drug Administration due to the Dietary Supplement Health and Education Act of 1994.”
The claim is substantially accurate. DSHEA (1994) does exempt collagen supplements from FDA premarket approval and shifts the burden of proving unsafety to the FDA, which multiple peer-reviewed and medical sources confirm. However, "largely unregulated" overstates the situation: the FDA retains meaningful post-market authority including cGMP manufacturing standards, labeling enforcement, adulteration removal powers, and premarket safety review for new dietary ingredients. A more precise framing would be "largely exempt from premarket approval requirements" rather than "largely unregulated."
“The United States Food and Drug Administration has approved leucovorin as a broad treatment for autism.”
This claim is false. The FDA approved leucovorin in March 2026 only for cerebral folate deficiency (CFD), an ultra-rare genetic condition affecting roughly 1 in a million people — not for autism. Leucovorin remains investigational for autism, the American Academy of Pediatrics does not recommend its routine use for autistic children, and a key study supporting leucovorin's autism benefits was retracted in January 2026 due to data irregularities. No FDA-approved broad treatment for autism spectrum disorder exists.
“Bioidentical hormones are chemically identical in molecular structure to hormones naturally produced by the human body.”
The claim is true. The Endocrine Society and the National Academies of Sciences both explicitly define bioidentical hormones as compounds with the exact same chemical and molecular structure as hormones naturally produced by the human body. This is the established scientific definition of the term. While compounded bioidentical products may lack FDA verification of their molecular identity, the claim itself is an accurate definitional statement supported by authoritative medical sources.